NEEDHAM, Mass., May 6 Celldex Therapeutics, Inc. (Nasdaq: CLDX), an antibody-based combination immunotherapy company, today announced that four presentations on clinical data from three of its product candidates will be made at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will take place at McCormick Place in Chicago from June 4-8, 2010.
Advertisement
"The Celldex oncology pipeline is well represented in this selection of clinical abstracts," said Anthony Marucci, President and Chief Executive Officer at Celldex Therapeutics. "Our innovative immunological approach to treating cancer continues to show great promise and furthers us toward our goal of bringing patients new, highly targeted therapies."
Advertisement
The company will be presenting promising data from the following studies:
Abstracts can be accessed after May 20, 2010 through the ASCO website, www.asco.org. All posters will be accessible from Celldex's website at www.celldextherapeutics.com after they are presented.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization (by Celldex and others) of CDX-110, CDX-1307, CDX-011, CDX-1135 (formerly TP10), CDX-1401, CDX-1127, Belinostat and other products. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital on acceptable terms, or at all; our ability to adapt APC Targeting Technology(TM) to develop new, safe and effective vaccines against oncology and infectious disease indications; our ability to successfully complete product research and further development of our programs; our development partners' willingness to make announcements with respect to co-developed products; the uncertainties inherent in clinical testing; our ability to manage research and development efforts for multiple products at varying stages of development; Pfizer's and our strategy and business plans concerning the continued development and commercialization of CDX-110; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; our ability to successfully integrate the businesses, multiple technologies and programs of CuraGen and Celldex; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
PF-04948568 (CDX-110) in Glioblastoma Multiforme: Poster Discussion Session ------------------------- Abstract Title: Interim data for ACT III: Phase II trial of PF- 04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). Presentation Date/Time: Saturday, June 5, 2010; 8:00 AM - 12:00 PM with poster discussion from 12:00 - 12:15 PM Presenter: Rose Lai, MD MSc, Assistant Professor of Neurology, The Neurological Institute of Columbia University, Brain Tumor Center Abstract Control Number: 53835 Permanent Abstract ID: 2014 Location: S103, Poster Board #6, with discussion in S100b CDX-011 in Advanced Melanoma: Poster Discussion Session ------------------------- Abstract Title: Frequent dosing and GPNMB expression with CDX- 011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. Presentation Date/Time: Monday, June 7, 2010; 8:00 AM - 12:00 PM with poster discussion from 11:00 AM - 12:00 PM Presenter: Omid Hamid, MD, The Angeles Clinic and Research Institute, Santa Monica, CA Abstract Control Number: 51525 Permanent Abstract ID: 8525 Location: S403, Poster Board #13, with discussion in S406 (Vista Room) CDX-011 in Breast Cancer: General Poster Session ---------------------- Abstract Title: Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE). Presentation Date/Time: Saturday, June 5, 2010; 2:00 PM -6:00 PM Presenter: Mansoor N. Saleh, MD, Georgia Cancer Specialists, Atlanta, GA Abstract Control Number: 51830 Permanent Abstract ID: 1095 Location: S Hall A2, Poster Board #30C CDX-1307 in Muscle-invasive Bladder Cancer: Trials in Progress Poster Session --------------------------------- Abstract Title: A randomized phase II study of a novel antigen- presenting cell-targeted hCG-beta vaccine (the CDX-1307 regimen) in muscle-invasive bladder cancer. Presentation Date/Time: Monday, June 7 2010; 8:00 AM - 12:00 PM Presenter: Deborah Ann Bradley, MD, Duke University Medical Center, Durham, NC Abstract Control Number: 51567 Permanent Abstract ID: TPS228 Location: S Hall A2, Poster Board #41G
SOURCE Celldex Therapeutics, Inc.
